Vivek Subbiah, MD

Beyond excited to recruit @VivekSubbiah to @nyulangone @Perlmutter_CC as the new director of our Early Phase Drug Development Program and the Rare Cancer Program. Congratulate Vivek when you see him at #ESMO26. Welcome to NYC! @JohnPLeonardMD https://t.co/sJKbZI0PDc https://t.co/LZZlrh8P9G

ADC drug development is accelerating. But is biomarker science keeping pace? Nearly 50% of ADC trials require no biomarker, while most that do still rely on conventional IHC. In our new @NatRevClinOncol review published just in time pre-#ESMO26, we propose a modular framework to bridge this gap - moving beyond target expression to the multiple biological determinants of ADC efficacy and toxicity. Proud to lead this international effort with @BarbaraPistill2 @nedmcnamee @rreddel @VivekSubbiah and colleagues. 🔗: https://t.co/afCu0r9vP1

Chicago is ready for all #ASCO26 attendees. @BalazsHalmosMD @PGrivasMDPhD @LeonidasPlatan1 @Dr_AmerZeidan @thenasheffect @VivekSubbiah Are you ready? https://t.co/TmgLNTqzjJ

#ESMO2026 | Drugging the Undruggable: A New Era in Precision Oncology “Undruggable” was never about the target. It was about our tools. An inspiring presentation by Dr. Vivek Subbiah (@VivekSubbiah) at ESMO 2026, highlighting how previously untargetable cancer drivers are becoming therapeutically actionable. From KRAS inhibition and p53 reactivation to MYC targeting, protein degradation, synthetic lethality, and AI-driven drug discovery, precision oncology is entering a new era. The next challenge is not only developing new drugs, but identifying the right molecular target in the right patient. Comprehensive genomic profiling and ctDNA testing will play an increasingly important role in this transformation. #ESMO26 @myESMO @VivekSubbiah #PrecisionOncology #UndruggableTargets #KRAS #TP53 #GenomicTesting #LiquidBiopsy @Dr_R_Kurzrock

Was going to open my hotel window for some fresh air but met this 🕷️ on the 44th floor at #ASCO26 😱 Floor 44. Chicago wind. Eight legs. This spider clearly didn’t get the memo about targeted therapy — it’s attaching to everything nonspecifically 🎯 @VivekSubbiah Calling all biology experts here: is this thing resistant? We need a magic bullet. Preferably an ADC with a spider-specific payload and a cleavable linker. 🧬🕸️ @PTarantinoMD

The trio is finally reunited! 🎉 What a pleasure to catch up with my great friends and colleagues @VivekSubbiah @Timothee_MD at #ESMO2026 in Madrid! And what better occasion to celebrate our latest publication in the Journal of Clinical Oncology! 🍾 https://t.co/EJakjdxkuC… Great science, stimulating discussions, friendship, and a shared passion for challenging established thinking and improving cancer care. Because science is even better when you get to share the journey with people you genuinely enjoy working with! Here’s to collaboration, and many more papers together! 🥂 #ESMO26 #ESMOAmbassadors #JCO #Immunotherapy #Oncology #CancerResearch #Collaboration

🚨Another big win for #precisionmedicine 🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma. ⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- the then CMO of @Relay_Tx “Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram 👉🏼Link to FDA approval https://t.co/8WTjhiTD98 👉🏼Link to @CD_AACR @AACR bench to bedside publication https://t.co/HeME5d8mRZ

⭐️Really loving the wording in the daraxonrasib FDA approval. Clear autonomy for physicians, centered on patient needs. 👉🏼“The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy” 👉🏼This is how oncology should move forward @OncoAlert @matthewherper @oncodaily @OpenEvidence @FDA @FDAOncology @FDAMedia @DrSamuelBHume

FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer | OncLive https://t.co/DyRWydmPht

⭐️So nice to meet with the @NCIDirector Dr. Letai @AACR #AACR26 ⭐️We need an all‑hands‑on‑deck approach from everyone to beat cancer. These are the best times in oncology research - we’re finally going after the “undruggable,” targets and it’s incredible to have @NCICancerTrials @NCIMedia @NIH in the mission to cure cancer @OncoAlert @oncodaily @AACRPres @AACR_CEO @DrChoueiri @AACRFoundation

Daraxonrasib is being branded as “Rasonque”. Sounds like a French perfume inspired by the switch‑II pocket. “Rasonque: Lock the switch‑II pocket down, quiet the effector binding, & let the MAPK pathway finally take a nap” @OncoAlert 🤔 cc @BalazsHalmosMD @chadinabhan https://t.co/5xvln7hJnF